Pharmaceutically acceptable starch

Details Pharmaceutically acceptable starch Pharmaceutically acceptable starch

2006-10-10

2006-10-10

Jiang, Shaojia (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C514S060000

Reexamination Certificate

active

07119195

ABSTRACT:
Production of purified, parenterally administrable starch by washing starch containing more than 85% amylopectin in order to remove surface-localized proteins, lipids and endotoxins, dissolving the starch in aqueous medium, molecular weight reduction by shearing, and optionally removal of residual water-soluble proteins, preferably by anion exchange chromatography.Purified starch and microparticles based on such starch.

REFERENCES:
patent: 3691090 (1972-09-01), Kitajima et al.
patent: 3737337 (1973-06-01), Schnoring et al.
patent: 3870704 (1975-03-01), Yoshida et al.
patent: 3881991 (1975-05-01), Kurimotor et al.
patent: 3909288 (1975-09-01), Powell et al.
patent: 4389330 (1983-06-01), Tice et al.
patent: 4517022 (1985-05-01), Harvey
patent: 4713249 (1987-12-01), Schröder
patent: 5319046 (1994-06-01), Kozulic et al.
patent: 5407609 (1995-04-01), Tice et al.
patent: 5424302 (1995-06-01), Nitsch
patent: 5455342 (1995-10-01), Redding, Jr.
patent: 5470582 (1995-11-01), Supersaxo et al.
patent: 5578709 (1996-11-01), Woiszwillo et al.
patent: 5622657 (1997-04-01), Takeda et al.
patent: 5654010 (1997-08-01), Johnson et al.
patent: 5667808 (1997-09-01), Johnson et al.
patent: 5753234 (1998-05-01), Lee et al.
patent: 5776885 (1998-07-01), Orsolini et al.
patent: 5945528 (1999-08-01), Sommermeyer et al.
patent: 5959102 (1999-09-01), Wasserman et al.
patent: 5981719 (1999-11-01), Woiszwillo et al.
patent: 6010574 (2000-01-01), Jeffcoat et al.
patent: 6248268 (2001-06-01), Cook et al.
patent: 0 008 241 (1980-02-01), None
patent: 0 213 303 (1987-03-01), None
patent: 0 540 582 (1994-08-01), None
patent: 0 688 429 (1998-02-01), None
patent: 0 330 180 (1999-03-01), None
patent: 11302156 (1999-11-01), None
patent: WO 90/13780 (1990-11-01), None
patent: WO 93/21008 (1993-10-01), None
patent: WO 94/12158 (1995-06-01), None
patent: WO 96/10042 (1996-04-01), None
patent: WO 97/14408 (1997-04-01), None
patent: WO 99/00425 (1999-01-01), None
patent: WO 99/20253 (1999-04-01), None
US 5,849,884, 12/1998, Woiszwillo et al. (withdrawn)
“Formation and Isolation of Spherical Fine Protein Microparticles Through Lyophilization of Protein—Poly(ethylene glycol) Aqueous Mixture”, Takahiro Morita et al., Pharmaceutical Research, vol. 17, 11, 2000, pp. 1367-1373.
Protein encapsulation into biodegradable microspheres by a novel S/O/W encapsulation method using poly(ethylene glycol) as a protein micronization adjuvant, Takahiro Morita et al., Journal of Controlled Release, 69 (2000) pp. 435-444.
Artursson et al., “Characterization of Polyacryl Starch Microparticles as Carriers for Proteins and Drugs,”Journal of Pharmaceutical Sciences, vol. 73, No. 11, pp. 1507-1513, (1984).
Franssen et al., “A Novel Preparation Method for Polymeric Microparticles Without the Use of Organic Solvents,”International Journal of Pharmaceutics, vol. 168, pp. 1-7 (1998).
Fu et al., “Visual Evidence of Acidic Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA) Microspheres”Pharmaceutical Research, vol. 17, No. 1, pp. 100-106 (2000).
Laakso et al., “Biodegradable Microspheres IV: Factors Affecting the Distribution and Degradation of Polyacryl Starch Microparticles,”Journal of Pharmaceutical Sciences, vol. 75, No. 10, pp. 962-967 (1986).
Laakso et al., “Biodegradable Microspheres X: Some Properties of Polyacryl Starch Microparticles Prepared from Acrylic Acid-Esterified Starch,”Journal of Pharmaceutical Sciences, vol. 76, No. 12, pp. 935-939 (1987).
Schröder, “Crystallized Carbohydrate Spheres as a Show Release Matrix for Biologically Active Substances,”Biomaterials, vol. 5, pp. 100-104 (1984).
Schröder, “Crystallized Carbohydrate Spheres for Slow Release and Targeting,”Enzymology, vol. 112, No. 9, pp. 116-128 (1985).
Stenekes et al., “The Preparation of Dextran Microspheres in an All-Aqueous System: Effect of the Formulation Parameters on Particle Characteristics,”Pharmaceutical Research, vol. 15, No. 4 pp. 557-561 (1998).
Stjärnkvist et al., “Biodegradable Microspheres XIII: Properties of the Crosslinking Chains in Polyacryl Starch Microparticles,”Journal of Pharmaceutical Sciences, vol. 78, No. 1, pp. 52-56 (1989).
Agersø et al., “Plasma Concentration of hGH and anti-hGH Antibodies After Subcutaneous Administration of hGH for 3 Weeks to Immunosuppressed Pigs,”J. Pharmacol ToxicolNo. 41 pp. 1-8 (1999).
Johnson et al., “A Month-Long effect From a Single Injection of Microencapsulated Human Growth Hormone,”Nature Medicine, vol. 2, No. 7 pp. 795-799 (1996).
Putney, “Encapsulation of Proteins for Improved Delivery,” Current Opinion inChemical Biology, Nol. 2, pp. 548-552 (1998).
“Clean Package Insert,” Nutropin Depot (somatropin(rDNA origin) for injectable suspension, Genentech, Inc., 1 DNA Way, South San Francisco, CA 940-4990, pp. 1-6 (Dec. 13, 1999).

Affiliated with

Also associated with

Rating

Pharmaceutically acceptable starch does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutically acceptable starch, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically acceptable starch will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3660517